Last Update 11 Mar 26

HCAT: Lowered Sector Outlook Will Set Up Cautiously Optimistic 2026 Rebound

Analysts have trimmed their price target on Health Catalyst by $0.50 to $2.75. This reflects a more cautious view on near term sector challenges, while they maintain a neutral stance on the shares.

Analyst Commentary

Recent commentary around Health Catalyst centers on reset expectations and a more measured view of the health tech group after a difficult 2025, with the revised US$2.75 price target highlighting both perceived risks and potential upside if execution improves.

Bullish Takeaways

Bullish analysts see the reaffirmed Neutral stance, despite a lower price target, as a sign that the current valuation already reflects many of the sector headwinds highlighted for 2025.
The inclusion of Health Catalyst in a 2026 outlook for health tech suggests the company remains relevant to investors who are selectively looking for names that could benefit if sector sentiment improves.
After a year where roughly one third of health tech peers saw share price declines greater than 25%, some bullish analysts view the recalibrated target as creating a clearer risk reward profile rather than a thesis break.
Cautious optimism on the broader health tech group into 2026 is seen as a potential support for valuation if Health Catalyst can deliver against operational goals and maintain balance sheet discipline.

Bearish Takeaways

Bearish analysts focus on the cut from US$3.25 to US$2.75 as a signal that previous expectations for execution and growth were too high, which can weigh on sentiment around the name.
The description of 2025 as another challenging year for health tech reinforces concerns that sector level pressures may continue to limit multiple expansion and constrain upside for Health Catalyst.
The maintained Neutral rating, even after reducing the target, is viewed by more cautious analysts as evidence that there is not yet a clear near term catalyst to re rate the shares.
With a large portion of the health tech group experiencing share price declines greater than 25% in 2025, some bearish analysts worry that investors may continue to prioritize companies with more visible growth and profitability profiles over Health Catalyst.

What's in the News

Health Catalyst appointed Ben Albert, previously President and COO, as Chief Executive Officer and board member, effective February 12, 2026. Former CEO Dan Burton moved to a strategic advisor role as part of an accelerated succession plan (Key Developments).
Albert joined Health Catalyst in January 2025 through its acquisition of Upfront Healthcare Services, where he was CEO and Co Founder, and has more than 25 years of experience building and leading healthcare organizations (Key Developments).
Upon becoming President and COO in September 2025, Albert conducted a comprehensive review of Health Catalyst's capabilities to focus resources on key business priorities. This may shape how investors think about execution under his leadership (Key Developments).
On January 21, 2026, Whetstone Capital Advisors signaled ongoing engagement with Health Catalyst and notified the company that it plans to submit a shareholder proposal aimed at changing elements of the company’s corporate governance (Key Developments).
The Whetstone proposal includes items such as declassifying the board, enabling shareholders to call special meetings and act by written consent, separating the CEO and Chair roles, and setting term limits for directors and nominating committee members (Key Developments).

Valuation Changes

Fair Value: The $3.88 fair value estimate is unchanged, suggesting no adjustment to the core valuation anchor in this update.
Discount Rate: The discount rate has fallen slightly from 11.83% to 11.72%, pointing to a modestly lower required return in the model.
Revenue Growth: The long term revenue growth assumption remains effectively the same at about a 15.09% decline, indicating no revision to the top line outlook used in the valuation work.
Net Profit Margin: The net profit margin assumption has fallen slightly from 6.93% to 6.33%, implying a bit less earnings power is being modeled on future revenues.
Future P/E: The future P/E multiple has risen moderately from 18.40x to 20.07x, signaling a small increase in the valuation multiple applied to projected earnings.

1 view

Key Takeaways

Expansion of AI-driven solutions and proprietary data assets, along with industry trends, will drive margin growth, premium pricing, and sustained revenue gains.
Platform migration and cost restructuring set the stage for improved profitability, operating leverage, and consistent technology segment growth.
Health Catalyst faces ongoing revenue pressure from client spending cuts, strategic downsizing, and macroeconomic headwinds, with uncertain prospects for sustained growth and profitability.

Catalysts

About Health Catalyst

Provides data and analytics technology and services to healthcare organizations in the United States.What are the underlying business or industry changes driving this perspective?

The company's focus on expanding its high-margin applications portfolio, driven by ongoing client cross-sell momentum and strong adoption of modular AI-enabled solutions, is positioned to accelerate gross margin expansion and adjusted EBITDA growth as macro headwinds stabilize (positively impacting margins and earnings).
Migration of platform clients to the new Ignite infrastructure is expected to largely complete by mid-2026, at which point the current revenue headwinds from clients "pocketing" migration cost savings will subside-setting the stage for renewed and more consistent Technology segment growth (positively impacting revenue trajectory).
Secular industry drivers-including the shift to value-based care and the demand for advanced data analytics to meet regulatory and efficiency goals-are expected to support ongoing demand for Health Catalyst's core offerings, expanding its addressable market and sustaining longer-term revenue growth.
Management's proactive cost restructuring, contract repricing, and organizational streamlining are on track to deliver $40 million in annualized profitability improvements, enabling sustainable operating leverage and improvements in net margin and free cash flow-well ahead of earlier targets.
The company's substantial investment in proprietary data assets, AI/ML-driven analytics, and its ability to leverage deep integration with over 1,100 healthcare clients position it to command premium pricing, foster high retention, and benefit disproportionately as digitization and AI adoption accelerate across the healthcare sector (driving both revenue and margin expansion).

Health Catalyst Earnings and Revenue Growth

Health Catalyst Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Health Catalyst's revenue will decrease by 0.4% annually over the next 3 years.
Analysts are not forecasting that Health Catalyst will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Health Catalyst's profit margin will increase from -31.7% to the average US Healthcare Services industry of 8.8% in 3 years.
If Health Catalyst's profit margin were to converge on the industry average, you could expect earnings to reach $28.1 million (and earnings per share of $0.33) by about September 2028, up from $-100.1 million today.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 18.4x on those 2028 earnings, up from -2.3x today. This future PE is lower than the current PE for the US Healthcare Services industry at 54.8x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 9.63%, as per the Simply Wall St company report.

Health Catalyst Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Significant and accelerated Medicaid and research funding cuts are causing widespread financial strain and uncertainty among Health Catalyst's core end markets-especially not-for-profit and academic medical center clients-which is leading to lower client spending, smaller extension contracts, and delayed bookings, directly impacting both near
and long-term revenue growth.
A pronounced trend of existing clients "pocketing" cost savings from Ignite platform migrations, rather than reinvesting these savings in expansion or new offerings, is compressing dollar-based net retention to the low 90s and creating persistent top-line headwinds that are expected to last at least through mid-2026.
The company's Professional Services segment faces strategic downsizing, including the exit of lower-margin or unprofitable contracts and workforce reductions impacting 9% of employees, resulting in immediate declines in Services revenue in 2025 and 2026, and introducing risk of weakened client support and scalability, negatively affecting both revenue and operating consistency.
Persistent macroeconomic pressures, such as inflation and potential expiration of premium subsidies, combined with industry conservatism and risk aversion, are causing health systems to defer or shrink technology spending, limiting the pace of Health Catalyst's pipeline conversion and new client acquisition and thus dampening revenue growth prospects for 2026 and possibly 2027.
The company's removal of ambitious 2028 revenue and EBITDA targets, stated cessation of near
to mid-term M&A activity, and reliance on maintaining profitability through restructuring rather than organic top-line growth, collectively raise concerns about Health Catalyst's ability to reignite sustainable revenue expansion-a risk that could constrain future earnings momentum and share price appreciation.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $4.556 for Health Catalyst based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $6.0, and the most bearish reporting a price target of just $3.5.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $320.3 million, earnings will come to $28.1 million, and it would be trading on a PE ratio of 18.4x, assuming you use a discount rate of 9.6%.
Given the current share price of $3.24, the analyst price target of $4.56 is 28.9% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Health Catalyst?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Modular AI Solutions Will Transform Value-Based Healthcare